21280081

Source:http://linkedlifedata.com/resource/pubmed/id/21280081

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0001721, umls-concept:C0008976, umls-concept:C0030567, umls-concept:C0034656, umls-concept:C0165921, umls-concept:C0871261, umls-concept:C1135159, umls-concept:C1704632, umls-concept:C1706817, umls-concept:C1882417, umls-concept:C2911692
pubmed:issue	1
pubmed:dateCreated	2011-1-31
pubmed:abstractText	In Parkinson disease (PD), the selective C-O-methyltransferase (COMT) inhibitor entacapone prolongs the effect of levodopa on motor symptoms (ON time) by increasing its bioavailability. The COMT Val158Met polymorphism is equally distributed in PD patients and modulates COMT activity, which can be high (Val/Val, COMT(HH) ), intermediate (Val/Met, COMT(HL) ), or low (Met/Met, COMT(LL) ). The objective of this study was to determine the response to entacapone in COMT(HH) and COMT(LL) PD patients.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7707449
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antiparkinson Agents, http://linkedlifedata.com/resource/pubmed/chemical/Catechol O-Methyltransferase, http://linkedlifedata.com/resource/pubmed/chemical/Catechols, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Levodopa, http://linkedlifedata.com/resource/pubmed/chemical/Methionine, http://linkedlifedata.com/resource/pubmed/chemical/Nitriles, http://linkedlifedata.com/resource/pubmed/chemical/Valine, http://linkedlifedata.com/resource/pubmed/chemical/entacapone
pubmed:status	MEDLINE
pubmed:month	Jan
pubmed:issn	1531-8249
pubmed:author	pubmed-author:AgidYvesY, pubmed-author:BellangerAgnèsA, pubmed-author:Ben DjebaraMounaM, pubmed-author:BonnetAnne-MarieAM, pubmed-author:BonnetCéciliaC, pubmed-author:Charbonnier-BeaupelFannyF, pubmed-author:CorvolJean-ChristopheJC, pubmed-author:CostentinJeanJ, pubmed-author:FiévetMarie-HélèneMH, pubmed-author:HartmannAndreasA, pubmed-author:HulotJean-SébastienJS, pubmed-author:LacomblezLucetteL, pubmed-author:MeliksetyanGayanéG, pubmed-author:RozeEmmanuelE, pubmed-author:VidailhetMarieM, pubmed-author:VrignaudCédricC, pubmed-author:ZahrNoëlN
pubmed:copyrightInfo	Copyright © 2010 American Neurological Association.
pubmed:issnType	Electronic
pubmed:volume	69
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	111-8
pubmed:meshHeading	pubmed-meshheading:21280081-Aged, pubmed-meshheading:21280081-Antiparkinson Agents, pubmed-meshheading:21280081-Biological Availability, pubmed-meshheading:21280081-Catechol O-Methyltransferase, pubmed-meshheading:21280081-Catechols, pubmed-meshheading:21280081-Cross-Over Studies, pubmed-meshheading:21280081-Double-Blind Method, pubmed-meshheading:21280081-Enzyme Inhibitors, pubmed-meshheading:21280081-Female, pubmed-meshheading:21280081-Genotype, pubmed-meshheading:21280081-Humans, pubmed-meshheading:21280081-Levodopa, pubmed-meshheading:21280081-Male, pubmed-meshheading:21280081-Methionine, pubmed-meshheading:21280081-Middle Aged, pubmed-meshheading:21280081-Nitriles, pubmed-meshheading:21280081-Parkinson Disease, pubmed-meshheading:21280081-Pharmacogenetics, pubmed-meshheading:21280081-Polymorphism, Genetic, pubmed-meshheading:21280081-Valine
pubmed:year	2011
pubmed:articleTitle	The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
pubmed:affiliation	INSERM (French National Institute of Medical Research and Health), Clinical Investigation Center (CIC-9503), Pitié-Salpêtrière Hospital, Paris, France. jean-christophe.corvol@psl.aphp.fr
pubmed:publicationType	Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't